ADC Therapeutics SA (ADCT) Tops Q4 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- S&P 500 up, Nasdaq at record high as megacap tech stocks rise
- Oil slips on rise in Middle East crude exports and G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
Tweet
Share
E-mail
Get Alerts ADCT Hot Sheet
Join SI Premium – FREE
ADC Therapeutics SA (NYSE: ADCT) reported Q4 EPS of ($0.09), $0.20 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $23.06 million versus the consensus estimate of $19.11 million.
For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- National Bank Holdings (NBHC) PT Lowered to $43 at DA Davidson
- MercadoLibre (MELI) call put ratio 1 call to 2.2 puts with a focus on October puts as share price up 6.7%
- Petrobras (PBR) call put ratio 6.4 calls to 1 put with a focus on December 26 and 27 calls as share price up 9.4%
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
